Revumenib plus standard drugs for NPM1 or KMT2A AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests adding a new targeted drug, revumenib, to two standard AML medicines (azacitidine and venetoclax) for adults with a specific gene change (NPM1 mutation or KMT2A rearrangement) who cannot receive strong chemotherapy. The goal is to see if the combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a new diagnosis of AML with either an NPM1 mutation or a KMT2A rearrangement, confirmed by a central lab.
- You must be 18 or older and not able to get intensive chemotherapy (for example, due to age 75+ or certain health problems like heart, lung, or kidney issues).
- Your white blood cell count must be below 25,000 per microliter (can be lowered with hydroxyurea first).
- Your kidneys, liver, and heart must work well enough (based on blood tests and ECG).
- You cannot have had prior AML treatment, except hydroxyurea to control white blood cells.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
This trial tests a new drug, revumenib, combined with strong chemotherapy for people with a specific type of AML (NPM1 mutation). The goal is to see if adding revumenib helps treat the leukemia better than chemo alone.
Hear when a new Acute Myeloid Leukemia, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.